Key Highlights

  • Immuron Limited entered an exclusive U.S. distribution agreement with Calmino Group AB for PROIBS.
  • PROIBS is a medical device certified in Europe for treating bloating, abdominal discomfort, and bowel irregularity.
  • The deal broadens Immuron's digestive wellness lineup alongside its existing Travelan product.
  • The development is focused on distribution rather than clinical trials, regulatory milestones, or Capital raises.

Immuron Limited (NASDAQ: IMRN) entered into an exclusive distribution agreement within the United States with Calmino Group AB for PROIBS, broadening its digestive wellness lineup alongside Travelan.

What Happened

PROIBS is a medical device certified in Europe for treating bloating, abdominal discomfort, and bowel irregularity. While the news expands Immuron's commercial footprint, the development remains focused on distribution rather than clinical trials, regulatory milestones, or capital raises.

Market Reaction

The disclosed information does not include stock price or trading data for Immuron following the distribution agreement.

Outlook

Continued commercial rollout of PROIBS within the U.S. market represents the next relevant development for Immuron's digestive wellness portfolio.